{"gene":"CEBPA","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1988,"finding":"C/EBP (CEBPA) binds both the CCAAT homology and enhancer core homology sequences; a single gene product accounts for both binding activities, with a 14-kD DNA-binding domain identified by protease mapping, and a 60-amino-acid segment within this domain bears sequence similarity to myc and fos oncogenes.","method":"Bacterial expression of recombinant clone, in vitro DNA-binding assay, protease fragment analysis, sequence analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro binding with recombinant protein, domain mapping by proteolysis, foundational paper","pmids":["2850264"],"is_preprint":false},{"year":1991,"finding":"C/EBP alpha (CEBPA) protein is expressed in the late phase of adipocyte differentiation in 3T3-L1 cells, downstream of C/EBP beta and C/EBP delta, consistent with a regulatory cascade controlling terminal adipocyte differentiation; C/EBP beta and delta form heterodimers with C/EBP alpha and activate transcription from the serum albumin promoter.","method":"Western/Northern blotting during 3T3-L1 differentiation, transient transfection reporter assays, heterodimerization assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (expression timecourse, reporter assay, heterodimerization), highly cited foundational study","pmids":["1840554"],"is_preprint":false},{"year":1991,"finding":"C/EBP alpha (CEBPA) binds to and transactivates enhancer element II of hepatitis B virus in liver cells.","method":"EMSA (gel shift), transient cotransfection reporter assay","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro binding plus reporter assay, single lab","pmids":["1853580"],"is_preprint":false},{"year":1995,"finding":"C/EBP alpha (CEBPA) is required for hepatic glycogen storage, transcriptional induction of gluconeogenic enzymes (PEPCK and glucose-6-phosphatase), and lipid accumulation in hepatocytes and adipocytes; knockout mice die from neonatal hypoglycemia.","method":"Targeted gene deletion (knockout mouse), gene expression analysis, biochemical assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple defined phenotypic readouts, replicated through multiple metabolic endpoints","pmids":["7652557"],"is_preprint":false},{"year":1998,"finding":"C/EBP alpha binds to and transactivates the leptin gene promoter through a C/EBP binding motif; mutation of this motif reduces promoter activity approximately 10-fold and abolishes C/EBP alpha binding.","method":"Mutational analysis of promoter, EMSA, transient transfection reporter assay","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro binding and reporter assay with defined mutations, single lab","pmids":["9492033"],"is_preprint":false},{"year":1998,"finding":"C/EBP alpha (and C/EBP beta) induces both myeloid and eosinophil lineage commitment in multipotent hematopoietic progenitors; transactivation-independent C/EBP functions are required for eosinophil lineage commitment while transactivation-dependent functions are required for maturation.","method":"Forced expression of wild-type and transactivation-deficient C/EBP alleles in transformed multipotent progenitors (MEPs), conditional C/EBP allele activation, differentiation assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — structure-function analysis with multiple mutant alleles and conditional activation, clear phenotypic readouts","pmids":["9694805"],"is_preprint":false},{"year":2002,"finding":"Ras signaling enhances C/EBP alpha transcriptional activity to induce granulocytic differentiation by phosphorylation of serine 248 via a PKC-dependent pathway; S248A mutation abolishes both Ras-mediated transactivation enhancement and C/EBP alpha-induced granulocytic differentiation.","method":"Gal4-fusion transactivation assay, site-directed mutagenesis (S248A), in vivo phosphorylation assay, PKC inhibitor treatment, differentiation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — mutagenesis combined with in vivo phosphorylation assay and functional differentiation readout","pmids":["11978795"],"is_preprint":false},{"year":2003,"finding":"Dominant-negative C/EBP (A-C/EBP) forms stable inactive heterodimers with C/EBP beta in vitro and blocks mitotic clonal expansion during adipogenesis by preventing nuclear import of C/EBP beta, thereby inhibiting expression of C/EBP alpha and PPARgamma downstream.","method":"Adenoviral A-C/EBP expression in 3T3-L1 cells, immunofluorescence staining, DNA replication assays, flow cytometry for cell cycle","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal epistasis established with multiple cellular readouts and mechanism (nuclear import blockade)","pmids":["14688407"],"is_preprint":false},{"year":2004,"finding":"PI3K/Akt pathway activation in liver tumor cells causes PP2A-mediated dephosphorylation of C/EBP alpha at Ser193, blocking its growth inhibitory activity; mutation of Ser193 to Ala abolishes C/EBP alpha interaction with cdk2 and E2F-Rb complexes and prevents growth arrest.","method":"Site-directed mutagenesis (S193A), co-immunoprecipitation with cdk2 and E2F-Rb, growth arrest assay, pharmacological inhibition of PI3K/Akt and PP2A","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1/2 — mutagenesis with defined binding partners and functional readout, mechanistic pathway placement","pmids":["15107404"],"is_preprint":false},{"year":2006,"finding":"FLT3-activating mutations in AML inhibit C/EBP alpha function through ERK1/2-mediated phosphorylation at serine 21; the S21A mutation restores granulocytic differentiation, while the phosphomimetic S21D mutation does not, demonstrating this is the relevant phosphorylation site.","method":"Site-directed mutagenesis (S21A, S21D), stable expression in MV4;11 cells, pharmacological inhibition of FLT3/MEK, granulocytic differentiation assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1/2 — mutagenesis with phosphomimetic controls and functional differentiation readout, clear mechanism","pmids":["16446383"],"is_preprint":false},{"year":2008,"finding":"C/EBP alpha genome-wide co-occupies approximately 3350 genomic regions together with PPARgamma in adipocytes; most adipogenesis-induced genes are bound by both factors, and both C/EBP alpha and beta are required along with PPARgamma for robust adipocyte-specific gene expression.","method":"ChIP-chip (ChIP coupled to genome-wide tiling arrays), ChIP in 3T3-L1 adipocytes","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP analysis with functional validation, highly cited","pmids":["18981473"],"is_preprint":false},{"year":2009,"finding":"Calreticulin, induced by UPR/ER stress via the ATF6 pathway, binds to CEBPA mRNA and blocks its translation, suppressing C/EBP alpha protein expression and myeloid differentiation in AML.","method":"Conditional calreticulin expression in U937 cells, mRNA-protein interaction assay (calreticulin-CEBPA mRNA binding), reporter analysis of calreticulin promoter ERSE elements, patient sample analysis","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct mRNA-protein binding shown, functional consequence on CEBPA protein levels established, single lab","pmids":["19659458"],"is_preprint":false},{"year":2010,"finding":"C/EBP alpha directly regulates miR-34a expression during granulopoiesis; miR-34a targets E2F3 to block myeloid cell proliferation; AML samples with CEBPA mutations show reduced miR-34a and elevated E2F3 and E2F1.","method":"Reporter assay, ChIP, manipulation of miR-34a in AML blast cells, patient sample gene expression analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP shows direct binding, reporter assay confirms transcriptional regulation, functional rescue experiments","pmids":["20889924"],"is_preprint":false},{"year":2012,"finding":"RUNX1 directly binds the CEBPA promoter and a conserved +37 kb enhancer region (with 4 Runx1 binding sites); RUNX1 loss reduces Cebpa mRNA in myeloid progenitors; exogenous C/EBP alpha rescues granulopoiesis in Runx1-deleted marrow, establishing RUNX1 as a direct upstream regulator of CEBPA.","method":"ChIP, enhancer mutagenesis in reporter assay, RUNX1-ER inducible system with cycloheximide, Runx1 knockout mice, exogenous C/EBP alpha rescue","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP, mutagenesis, inducible system, genetic rescue, multiple orthogonal methods","pmids":["22451420"],"is_preprint":false},{"year":2013,"finding":"C/EBP alpha controls adult HSC quiescence; C/EBP alpha-deficient adult HSCs show increased proliferation and number; N-Myc is identified as a downstream target of C/EBP alpha, and C/EBP alpha loss causes de-repression of N-Myc.","method":"Inducible Cebpa knockout mouse, transcriptional profiling, functional HSC assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — inducible KO with defined molecular mechanism (N-Myc de-repression) and phenotypic readout","pmids":["23502316"],"is_preprint":false},{"year":2015,"finding":"p53 and KLF4 directly activate CEBPA gene transcription; in AML, p53 inactivation (correlated with elevated XPO1/CRM1, MDM2, CUL9/PARC) leads to reduced KLF4 and CEBPA protein levels; restoring p53 function induces CEBPA expression and myeloid differentiation.","method":"Reporter assays, protein level analysis in AML patient samples, pharmacological p53 restoration, differentiation assay","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay plus patient sample correlation plus pharmacological rescue, single lab","pmids":["26408402"],"is_preprint":false},{"year":2016,"finding":"A single enhancer at +42 kb from CEBPA is essential for CEBPA expression exclusively in hematopoietic stem cells and myeloid-primed progenitors; germline deletion of this enhancer in mice causes severe granulocytic defects and loss of HSC maintenance without affecting CEBPA expression in other organs.","method":"CRISPR/Cas9 enhancer deletion in mice (in vivo), chromatin topology analysis, gene expression profiling in sorted progenitors","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1/2 — in vivo enhancer deletion with clean lineage-specific phenotype, multiple readouts","pmids":["26966090"],"is_preprint":false},{"year":2017,"finding":"R-2HG inhibits FTO demethylase activity, increasing global m6A RNA modification, which decreases the stability of CEBPA (and MYC) transcripts in sensitive leukemia cells, suppressing relevant signaling pathways.","method":"FTO activity assay, m6A RNA sequencing, mRNA stability assay, ectopic IDH1 mutation expression, FTO overexpression/knockdown","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1/2 — enzymatic assay, transcriptome-wide m6A analysis, functional rescue, multiple orthogonal methods","pmids":["29249359"],"is_preprint":false},{"year":2017,"finding":"Small activating RNA (saRNA) targeting the CEBPA gene locus increases CEBPA transcription in a sequence-specific manner requiring Argonaute-2 (Ago2); the guide strand associates with Ago2 and localizes to the CEBPA genomic locus.","method":"Nuclear run-on assay, RNA ChIP (Ago2 association with CEBPA locus), saRNA gain-of-function in hepatocellular carcinoma cells","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 — nuclear run-on confirms transcriptional mechanism, RNA-ChIP confirms locus-specific Ago2 association, single lab","pmids":["28882451"],"is_preprint":false},{"year":2019,"finding":"Oncogenic C/EBP alpha p30 isoform (from N-terminal CEBPA mutations) physically interacts with the MLL1 histone-methyltransferase complex and co-localizes with MLL1 genome-wide; MLL1 complex loss causes differentiation arrest reversal in C/EBP alpha p30-expressing cells; GATA2 is identified as a direct critical target of the p30-MLL1 interaction.","method":"Co-immunoprecipitation (p30-MLL1 interaction), ChIP-seq (genome-wide co-localization), CRISPR/Cas9 MLL1 mutagenesis, pharmacological MLL1 complex inhibition, differentiation assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1/2 — reciprocal Co-IP, genome-wide ChIP-seq, CRISPR KO, pharmacological inhibition, multiple orthogonal methods","pmids":["30679799"],"is_preprint":false},{"year":2019,"finding":"The leukemia-associated CEBPA-p30 isoform occupies aberrantly activated enhancers and directly drives Nt5e/CD73 expression; CD73 sustains leukemic growth via the CD73/A2AR axis; targeting this pathway enhances survival of AML-transplanted mice.","method":"Microscale in vivo ChIP-seq, cross-species gene expression analysis (human AML and Cebpa Lp30 mouse model), functional CD73/A2AR pathway inhibition in vivo","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq with cross-species validation and in vivo therapeutic targeting","pmids":["31309149"],"is_preprint":false},{"year":2019,"finding":"Activating CSF3R mutations cooperate with loss-of-function CEBPA mutations to promote acute leukemia; mutant CEBPA prevents activation of a subset of myeloid lineage enhancers required for differentiation; CEBPA mutation must occur as the initial event in AML initiation.","method":"Mouse leukemia model with defined mutation order, chromatin/enhancer analysis, epistasis experiments","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis with mutation order experiments and enhancer mechanism, single lab","pmids":["31784538"],"is_preprint":false},{"year":2021,"finding":"Chronic IL-1β exposure selects for Cebpa-knockout hematopoietic progenitors because C/EBP alpha normally mediates IL-1β-induced differentiation and stem cell gene expression repression; Cebpa-KO HSPCs are resistant to these prodifferentiative effects and competitively expand; ectopic CEBPA reduces fitness of established human AML coinciding with increased differentiation.","method":"Competitive transplantation of Cebpa-KO vs wild-type HSPCs with chronic IL-1β treatment, gene expression profiling, ectopic CEBPA expression in human AML","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KO in competitive in vivo setting with mechanistic gene expression data and human AML validation","pmids":["33914855"],"is_preprint":false},{"year":2022,"finding":"CEBPA protein directly interacts with the long isoform DNMT3A (but not DNMT3A2) and blocks DNMT3A from accessing DNA substrate, thereby inhibiting its methyltransferase activity; tumor-associated CEBPA mutations (e.g., N321D) disrupt DNMT3A association and cause aberrant DNA hypermethylation at PRC2 target genes.","method":"Co-immunoprecipitation (CEBPA-DNMT3A interaction), in vitro methyltransferase activity assay with CEBPA blocking, bisulfite/methylation profiling of CEBPA mutant leukemia, mutagenesis of CEBPA interaction domain","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro enzymatic inhibition assay plus Co-IP, mutagenesis, and genome-wide methylation profiling","pmids":["35080973"],"is_preprint":false},{"year":2023,"finding":"The intrinsically disordered region (IDR) of CEBPA undergoes phase separation in vitro dependent on aromatic residues; CEBPA forms nuclear foci and promotes long-range 3D chromatin hubs at CEBPA-bound regions during B cell-to-macrophage transdifferentiation; phase separation may underlie foci formation and 3D genome organization.","method":"In vitro phase separation assay with IDR mutagenesis, live-cell imaging of CEBPA foci, Hi-C/chromatin conformation analysis (ChIP-seq, ATAC-seq), transdifferentiation model","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 1/2 — in vitro reconstitution plus live imaging plus chromatin conformation data, IDR mutagenesis; phase separation-function link in vivo remains correlative","pmids":["37516962"],"is_preprint":false},{"year":2024,"finding":"CEBPA restricts alveolar type 2 (AT2) cell plasticity by promoting the AT2 transcriptional program and recruiting the lung lineage transcription factor NKX2-1; without CEBPA, neonatal AT2 cells reactivate the SOX9 progenitor program, and after Sendai virus injury mature AT2 cells also aberrantly express SOX9 and more readily form KRT8/CLDN4+ transitional cells.","method":"Conditional Cebpa knockout in AT2 cells, ChIP/co-immunoprecipitation for CEBPA-NKX2-1 interaction, ATAC-seq (epigenetic maturation), viral injury model, immunofluorescence","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined molecular mechanism (NKX2-1 recruitment), epigenetic data, injury model, multiple readouts","pmids":["38755149"],"is_preprint":false},{"year":2003,"finding":"C/EBP alpha binds two regions of the bcl-2 P2 promoter and increases bcl-2 expression in t(14;18) lymphoma cells; siRNA-mediated knockdown of C/EBP alpha reduces Bcl-2 protein levels; in vivo binding confirmed by ChIP.","method":"Reporter assay, EMSA, ChIP, siRNA knockdown, Western blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro binding, in vivo ChIP, and functional loss-of-function with protein readout","pmids":["12970736"],"is_preprint":false},{"year":2018,"finding":"CEBPA acts as a pioneer factor in THP-1 monocytes, co-occupying approximately one-third of genomic VDR binding sites; CEBPA binding strength is modulated by 1,25(OH)2D3; CEBPA silencing reveals it enhances basal expression and ligand-inducibility of ~70 vitamin D target genes and suppresses ~82 others, with PU.1 occupancy on CEBPA enhancers mechanistically explaining the dichotomy.","method":"ChIP-seq (CEBPA cistrome), RNA-seq after CEBPA silencing, ChIP for H3K4me3 and PU.1","journal":"Biochimica et biophysica acta. Gene regulatory mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide ChIP-seq plus transcriptome after silencing, single lab","pmids":["30550771"],"is_preprint":false},{"year":2018,"finding":"STAT3 induces C/EBP alpha/beta expression, which suppresses MITF transcription by binding to the MITF enhancer region; ATAC-seq confirmed CEBPa/b binding to the MITF enhancer leads to silencing of the MITF locus in melanoma cells.","method":"STAT3 knockout mouse melanoma model, CEBP knockdown, ATAC-seq, gene expression profiling","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — ATAC-seq confirms CEBP binding to MITF enhancer with KO/KD functional consequence, single lab","pmids":["33323974"],"is_preprint":false},{"year":2018,"finding":"C/EBP alpha (CEBPA) controls cystatin F expression by binding to the CST7 gene promoter during monocyte differentiation; upon PMA-induced differentiation to macrophages, C/EBP alpha protein level decreases and its binding to the CST7 promoter is reduced, leading to decreased cystatin F and increased intracellular cysteine cathepsin activity.","method":"Chromatin immunoprecipitation (ChIP), co-immunoprecipitation, immunofluorescence confocal microscopy, proximity ligation assay","journal":"European journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms direct promoter binding, functional differentiation context established","pmids":["30033148"],"is_preprint":false}],"current_model":"CEBPA encodes a bZIP transcription factor that directly binds CCAAT/enhancer DNA sequences and functions as a master regulator of myeloid and adipocyte differentiation by activating lineage-specific gene programs, maintaining HSC quiescence through repression of N-Myc, inhibiting cell-cycle progression via interactions with CDKs and E2F-Rb complexes, directly blocking DNMT3A methyltransferase activity through physical interaction, undergoing phase separation through its intrinsically disordered region to form 3D chromatin hubs, and serving as a hub for post-translational regulation—including ERK1/2-mediated phosphorylation at Ser21 (inhibitory) and Ras/PKC-mediated phosphorylation at Ser248 (activating)—whose disruption through recurrent mutations drives acute myeloid leukemia by causing aberrant enhancer activation, epigenetic dysregulation, and differentiation block."},"narrative":{"teleology":[{"year":1988,"claim":"The initial question of what protein recognizes both CCAAT and enhancer core sequences was resolved by showing a single gene product (C/EBP) accounts for both activities, with a compact 14-kD DNA-binding domain bearing homology to myc/fos oncogenes, establishing CEBPA as a sequence-specific transcription factor.","evidence":"Recombinant protein expression, in vitro DNA-binding assay, and protease domain mapping","pmids":["2850264"],"confidence":"High","gaps":["No in vivo target gene identification","Dimerization partners not characterized","No physiological function established"]},{"year":1995,"claim":"The physiological necessity of CEBPA was established by showing knockout mice die neonatally from hypoglycemia due to failed hepatic glycogen storage, gluconeogenic enzyme induction, and adipocyte lipid accumulation, defining CEBPA as essential for metabolic gene programs.","evidence":"Targeted gene deletion in mice with metabolic and gene expression phenotyping","pmids":["7652557"],"confidence":"High","gaps":["Hematopoietic role not yet addressed in KO","Direct vs. indirect transcriptional targets not distinguished"]},{"year":1998,"claim":"Beyond metabolism, CEBPA was shown to be sufficient to induce myeloid and eosinophil lineage commitment in multipotent progenitors, with transactivation-independent functions required for lineage specification and transactivation-dependent functions for maturation, revealing separable differentiation mechanisms.","evidence":"Forced expression of wild-type and transactivation-deficient alleles in multipotent progenitors with differentiation assays","pmids":["9694805"],"confidence":"High","gaps":["In vivo hematopoietic requirement not yet shown","Downstream differentiation targets unknown"]},{"year":2002,"claim":"How signaling pathways tune CEBPA activity was answered by identifying two opposing phosphorylation events: Ras/PKC-mediated Ser248 phosphorylation enhances granulocytic differentiation, while FLT3/ERK1/2-mediated Ser21 phosphorylation inhibits it, establishing post-translational control as a regulatory axis exploited in AML.","evidence":"Site-directed mutagenesis (S248A, S21A, S21D), in vivo phosphorylation assays, PKC/MEK inhibitors, granulocytic differentiation assays in MV4;11 cells","pmids":["11978795","16446383"],"confidence":"High","gaps":["Full phosphoproteome of CEBPA not mapped","Kinase-substrate interaction structures not resolved"]},{"year":2004,"claim":"The mechanism by which CEBPA arrests cell growth was clarified: phosphorylation at Ser193 is required for physical interaction with CDK2 and E2F-Rb complexes, and PI3K/Akt-driven PP2A dephosphorylation at this site abolishes growth arrest, connecting metabolic signaling to cell-cycle control.","evidence":"S193A mutagenesis, co-immunoprecipitation with CDK2 and E2F-Rb, PI3K/Akt and PP2A pharmacological inhibition in liver tumor cells","pmids":["15107404"],"confidence":"High","gaps":["Structural basis of CDK2/E2F interaction not resolved","Relative contribution of each cell-cycle target unclear"]},{"year":2008,"claim":"Genome-wide occupancy analysis revealed that CEBPA co-occupies ~3350 sites with PPARγ in adipocytes, establishing that the two factors cooperatively regulate the adipogenic transcriptional program rather than acting independently.","evidence":"ChIP-chip genome-wide tiling arrays in 3T3-L1 adipocytes","pmids":["18981473"],"confidence":"High","gaps":["Causal hierarchy between CEBPA and PPARγ at co-bound sites not resolved","Enhancer vs. promoter function not distinguished"]},{"year":2013,"claim":"A key question about how HSCs maintain quiescence was addressed by showing that CEBPA-deficient adult HSCs hyperproliferate due to de-repression of N-Myc, establishing CEBPA as a direct regulator of HSC self-renewal independent of its differentiation function.","evidence":"Inducible Cebpa knockout mouse with transcriptional profiling and functional HSC assays","pmids":["23502316"],"confidence":"High","gaps":["Whether CEBPA directly binds N-Myc regulatory regions not confirmed by ChIP","Interaction with other quiescence regulators not explored"]},{"year":2016,"claim":"The cis-regulatory architecture controlling tissue-specific CEBPA expression was defined by showing a single +42 kb enhancer is essential exclusively for hematopoietic CEBPA expression; its deletion causes granulocytic failure and HSC loss without affecting non-hematopoietic organs.","evidence":"CRISPR/Cas9 enhancer deletion in mice with sorted progenitor gene expression profiling","pmids":["26966090"],"confidence":"High","gaps":["Trans-acting factors at this enhancer beyond RUNX1 not fully defined","Whether additional enhancers exist for fine-tuning within hematopoiesis"]},{"year":2019,"claim":"How N-terminal CEBPA mutations cause leukemia was mechanistically explained: the truncated p30 isoform recruits the MLL1 histone-methyltransferase complex to aberrant enhancers, directly activating GATA2 and the CD73/A2AR pathway to sustain leukemic growth and block differentiation.","evidence":"Reciprocal co-immunoprecipitation, ChIP-seq for p30 and MLL1, CRISPR MLL1 knockout, cross-species ChIP-seq, in vivo CD73 pathway inhibition","pmids":["30679799","31309149"],"confidence":"High","gaps":["How p30 gains MLL1 interaction absent in full-length CEBPA not structurally resolved","Complete set of aberrant p30 target enhancers not cataloged"]},{"year":2022,"claim":"A non-transcriptional function of CEBPA was uncovered: it directly binds the long DNMT3A isoform and physically blocks its access to DNA substrate, inhibiting methyltransferase activity; AML-associated C-terminal CEBPA mutations (e.g., N321D) disrupt this interaction, causing DNA hypermethylation at PRC2 targets.","evidence":"Co-immunoprecipitation, in vitro reconstituted methyltransferase inhibition assay, bisulfite methylation profiling of CEBPA-mutant leukemia","pmids":["35080973"],"confidence":"High","gaps":["Structural basis of CEBPA-DNMT3A interface not determined","Whether this mechanism operates in non-hematopoietic tissues unknown"]},{"year":2023,"claim":"CEBPA's intrinsically disordered region was shown to undergo phase separation in vitro and form nuclear foci that promote long-range 3D chromatin hubs during transdifferentiation, suggesting phase separation as a mechanism for CEBPA's pioneer-like genome reorganization activity.","evidence":"In vitro phase separation assay with IDR mutagenesis, live-cell imaging, Hi-C/chromatin conformation capture during B-to-macrophage transdifferentiation","pmids":["37516962"],"confidence":"Medium","gaps":["Causal link between phase separation and transcriptional output not established in vivo","Whether phase separation is required for normal hematopoiesis untested","IDR mutants not tested in differentiation functional assays"]},{"year":2024,"claim":"CEBPA's role was extended beyond hematopoiesis: in alveolar type 2 cells, CEBPA recruits the lung lineage factor NKX2-1 to maintain the AT2 program and restrict plasticity; without CEBPA, cells reactivate the SOX9 progenitor program and aberrantly generate transitional cell states after injury.","evidence":"Conditional Cebpa knockout in AT2 cells, ChIP/co-IP for CEBPA-NKX2-1 interaction, ATAC-seq, Sendai virus injury model","pmids":["38755149"],"confidence":"High","gaps":["Whether CEBPA-NKX2-1 interaction is direct or within a complex not resolved","Relevance to lung fibrosis or adenocarcinoma progression not tested"]},{"year":null,"claim":"Key unresolved questions include the structural basis of CEBPA interactions with DNMT3A and MLL1, whether phase separation is functionally required for CEBPA's transcriptional and pioneer activities in vivo, the full spectrum of CEBPA's non-transcriptional functions, and how CEBPA integrates multiple post-translational modifications to coordinate differentiation versus quiescence decisions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of CEBPA-DNMT3A or CEBPA-MLL1 complex","In vivo functional requirement for phase separation untested","Combinatorial phosphorylation code not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,10,27]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,5,10,13,16,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[24,25]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[10,24,27]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,5,10,13,16,25,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,3,5,14,25]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[8,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,19,20,21,23]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[23,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,22]}],"complexes":[],"partners":["PPARG","DNMT3A","MLL1","CDK2","NKX2-1","CEBPB","RUNX1","SPI1"],"other_free_text":[]},"mechanistic_narrative":"CEBPA encodes a bZIP transcription factor that binds CCAAT/enhancer DNA sequences and serves as a master regulator of myeloid differentiation, adipogenesis, and hepatic metabolism. CEBPA activates lineage-specific gene programs in cooperation with PPARγ in adipocytes and PU.1 in myeloid cells, maintains hematopoietic stem cell quiescence through repression of N-Myc, and inhibits cell-cycle progression via phosphorylation-dependent interactions with CDK2 and E2F-Rb complexes [PMID:18981473, PMID:23502316, PMID:15107404]. Its activity is modulated by post-translational phosphorylation—ERK1/2-mediated phosphorylation at Ser21 inhibits granulocytic differentiation while PKC-mediated phosphorylation at Ser248 enhances it—and by direct physical inhibition of the DNMT3A methyltransferase, linking CEBPA to epigenetic regulation [PMID:16446383, PMID:11978795, PMID:35080973]. Loss-of-function and N-terminal truncating CEBPA mutations drive acute myeloid leukemia by causing aberrant enhancer activation through recruitment of the MLL1 complex, differentiation block, and DNA hypermethylation at PRC2 target genes [PMID:30679799, PMID:31784538, PMID:35080973]."},"prefetch_data":{"uniprot":{"accession":"P49715","full_name":"CCAAT/enhancer-binding protein alpha","aliases":[],"length_aa":358,"mass_kda":37.6,"function":"Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Down-regulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex (PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC1. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity) Can act as dominant-negative. Binds DNA and have transctivation activity, even if much less efficiently than isoform 2. Does not inhibit cell proliferation (PubMed:14660596) Directly and specifically enhances ribosomal DNA transcription interacting with RNA polymerase I-specific cofactors and inducing histone acetylation","subcellular_location":"Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/P49715/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CEBPA","classification":"Not Classified","n_dependent_lines":56,"n_total_lines":1208,"dependency_fraction":0.046357615894039736},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CEBPA","total_profiled":1310},"omim":[{"mim_id":"621163","title":"ADIPOGENESIS REGULATORY FACTOR; ADIRF","url":"https://www.omim.org/entry/621163"},{"mim_id":"620560","title":"CEBPA DIVERGENT TRANSCRIPT; CEBPA-DT","url":"https://www.omim.org/entry/620560"},{"mim_id":"619640","title":"LYSINE DEMETHYLASE 7A; KDM7A","url":"https://www.omim.org/entry/619640"},{"mim_id":"619246","title":"SPEXIN HORMONE; SPX","url":"https://www.omim.org/entry/619246"},{"mim_id":"618819","title":"PBX HOMEOBOX-INTERACTING PROTEIN 1; PBXIP1","url":"https://www.omim.org/entry/618819"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":92.7},{"tissue":"breast","ntpm":67.7},{"tissue":"liver","ntpm":198.2},{"tissue":"skin 1","ntpm":115.0}],"url":"https://www.proteinatlas.org/search/CEBPA"},"hgnc":{"alias_symbol":["C/EBP-alpha"],"prev_symbol":["CEBP"]},"alphafold":{"accession":"P49715","domains":[{"cath_id":"1.20.5","chopping":"288-358","consensus_level":"medium","plddt":92.2892,"start":288,"end":358}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49715","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49715-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49715-F1-predicted_aligned_error_v6.png","plddt_mean":61.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CEBPA","jax_strain_url":"https://www.jax.org/strain/search?query=CEBPA"},"sequence":{"accession":"P49715","fasta_url":"https://rest.uniprot.org/uniprotkb/P49715.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49715/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49715"}},"corpus_meta":[{"pmid":"1840554","id":"PMC_1840554","title":"Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.","date":"1991","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1840554","citation_count":1511,"is_preprint":false},{"pmid":"2850264","id":"PMC_2850264","title":"Isolation of a recombinant copy of the gene encoding C/EBP.","date":"1988","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/2850264","citation_count":926,"is_preprint":false},{"pmid":"29249359","id":"PMC_29249359","title":"R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29249359","citation_count":908,"is_preprint":false},{"pmid":"7652557","id":"PMC_7652557","title":"Impaired energy homeostasis in C/EBP alpha knockout mice.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7652557","citation_count":815,"is_preprint":false},{"pmid":"18981473","id":"PMC_18981473","title":"PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale.","date":"2008","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18981473","citation_count":688,"is_preprint":false},{"pmid":"8137425","id":"PMC_8137425","title":"C/EBP is an immediate-early gene required for the consolidation of long-term facilitation in Aplysia.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8137425","citation_count":474,"is_preprint":false},{"pmid":"10619021","id":"PMC_10619021","title":"A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10619021","citation_count":276,"is_preprint":false},{"pmid":"15944395","id":"PMC_15944395","title":"Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15944395","citation_count":237,"is_preprint":false},{"pmid":"8530141","id":"PMC_8530141","title":"The C/EBP family of transcription factors.","date":"1995","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/8530141","citation_count":220,"is_preprint":false},{"pmid":"23160954","id":"PMC_23160954","title":"C/EBP transcription factors mediate epicardial activation during heart development and injury.","date":"2012","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23160954","citation_count":188,"is_preprint":false},{"pmid":"16446383","id":"PMC_16446383","title":"Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16446383","citation_count":172,"is_preprint":false},{"pmid":"14688407","id":"PMC_14688407","title":"Dominant-negative C/EBP disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14688407","citation_count":157,"is_preprint":false},{"pmid":"14759369","id":"PMC_14759369","title":"Ras induces mediator complex exchange on C/EBP beta.","date":"2004","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/14759369","citation_count":147,"is_preprint":false},{"pmid":"11353682","id":"PMC_11353682","title":"Altered expression of C/EBP family members results in decreased adipogenesis with aging.","date":"2001","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11353682","citation_count":145,"is_preprint":false},{"pmid":"15985538","id":"PMC_15985538","title":"Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15985538","citation_count":127,"is_preprint":false},{"pmid":"15107404","id":"PMC_15107404","title":"Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15107404","citation_count":123,"is_preprint":false},{"pmid":"9492033","id":"PMC_9492033","title":"Regulation of leptin promoter function by Sp1, C/EBP, and a novel factor.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9492033","citation_count":122,"is_preprint":false},{"pmid":"23502316","id":"PMC_23502316","title":"C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence.","date":"2013","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23502316","citation_count":119,"is_preprint":false},{"pmid":"29464001","id":"PMC_29464001","title":"PIWIL3/OIP5-AS1/miR-367-3p/CEBPA feedback loop regulates the biological behavior of glioma cells.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/29464001","citation_count":117,"is_preprint":false},{"pmid":"34320176","id":"PMC_34320176","title":"CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34320176","citation_count":114,"is_preprint":false},{"pmid":"20889924","id":"PMC_20889924","title":"C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20889924","citation_count":112,"is_preprint":false},{"pmid":"10319019","id":"PMC_10319019","title":"The C/EBP family of transcription factors in the liver and other organs.","date":"1998","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10319019","citation_count":104,"is_preprint":false},{"pmid":"1853580","id":"PMC_1853580","title":"Transcriptional factor C/EBP binds to and transactivates the enhancer element II of the hepatitis B virus.","date":"1991","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/1853580","citation_count":100,"is_preprint":false},{"pmid":"28882451","id":"PMC_28882451","title":"Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.","date":"2017","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28882451","citation_count":94,"is_preprint":false},{"pmid":"9694805","id":"PMC_9694805","title":"Distinct C/EBP functions are required for eosinophil lineage commitment and maturation.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9694805","citation_count":92,"is_preprint":false},{"pmid":"12661007","id":"PMC_12661007","title":"Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.","date":"2003","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12661007","citation_count":92,"is_preprint":false},{"pmid":"19706798","id":"PMC_19706798","title":"Complexity of CEBPA dysregulation in human acute myeloid leukemia.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19706798","citation_count":89,"is_preprint":false},{"pmid":"22451420","id":"PMC_22451420","title":"Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22451420","citation_count":86,"is_preprint":false},{"pmid":"21389327","id":"PMC_21389327","title":"IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21389327","citation_count":83,"is_preprint":false},{"pmid":"15936952","id":"PMC_15936952","title":"A transcriptional role for C/EBP beta in the neuronal response to axonal injury.","date":"2005","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/15936952","citation_count":79,"is_preprint":false},{"pmid":"23720735","id":"PMC_23720735","title":"C/EBP homologous protein-induced macrophage apoptosis protects mice from steatohepatitis.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23720735","citation_count":76,"is_preprint":false},{"pmid":"29511346","id":"PMC_29511346","title":"Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29511346","citation_count":74,"is_preprint":false},{"pmid":"32430494","id":"PMC_32430494","title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32430494","citation_count":71,"is_preprint":false},{"pmid":"26966090","id":"PMC_26966090","title":"An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26966090","citation_count":71,"is_preprint":false},{"pmid":"15289464","id":"PMC_15289464","title":"Effect of a C/EBP gene replacement on mitochondrial biogenesis in fat cells.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15289464","citation_count":69,"is_preprint":false},{"pmid":"30135303","id":"PMC_30135303","title":"Localized hypoxia links ER stress to lung fibrosis through induction of C/EBP homologous protein.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30135303","citation_count":67,"is_preprint":false},{"pmid":"20439707","id":"PMC_20439707","title":"C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20439707","citation_count":65,"is_preprint":false},{"pmid":"11978795","id":"PMC_11978795","title":"Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11978795","citation_count":65,"is_preprint":false},{"pmid":"24351550","id":"PMC_24351550","title":"C/EBP homologous protein drives pro-catabolic responses in chondrocytes.","date":"2013","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24351550","citation_count":62,"is_preprint":false},{"pmid":"29695233","id":"PMC_29695233","title":"Apigetrin inhibits adipogenesis in 3T3-L1 cells by downregulating PPARγ and CEBP-α.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29695233","citation_count":59,"is_preprint":false},{"pmid":"21134981","id":"PMC_21134981","title":"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.","date":"2010","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/21134981","citation_count":57,"is_preprint":false},{"pmid":"10582601","id":"PMC_10582601","title":"Activation and degradation of the transcription factor C/EBP during long-term facilitation in Aplysia.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10582601","citation_count":56,"is_preprint":false},{"pmid":"33914855","id":"PMC_33914855","title":"Chronic interleukin-1 exposure triggers selection for Cebpa-knockout multipotent hematopoietic progenitors.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33914855","citation_count":52,"is_preprint":false},{"pmid":"12821655","id":"PMC_12821655","title":"Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12821655","citation_count":51,"is_preprint":false},{"pmid":"7664842","id":"PMC_7664842","title":"Normal fibroblasts induce the C/EBP beta and ATF-4 bZIP transcription factors in response to anoxia.","date":"1995","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/7664842","citation_count":51,"is_preprint":false},{"pmid":"33323974","id":"PMC_33323974","title":"STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33323974","citation_count":49,"is_preprint":false},{"pmid":"28637622","id":"PMC_28637622","title":"Familial CEBPA-mutated acute myeloid leukemia.","date":"2017","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28637622","citation_count":49,"is_preprint":false},{"pmid":"28273455","id":"PMC_28273455","title":"A Bach2-Cebp Gene Regulatory Network for the Commitment of Multipotent Hematopoietic Progenitors.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28273455","citation_count":48,"is_preprint":false},{"pmid":"12606546","id":"PMC_12606546","title":"Transcription cooperation by NFAT.C/EBP composite enhancer complex.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12606546","citation_count":48,"is_preprint":false},{"pmid":"24653623","id":"PMC_24653623","title":"MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma.","date":"2014","source":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","url":"https://pubmed.ncbi.nlm.nih.gov/24653623","citation_count":47,"is_preprint":false},{"pmid":"36471363","id":"PMC_36471363","title":"LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36471363","citation_count":45,"is_preprint":false},{"pmid":"22242125","id":"PMC_22242125","title":"Stress-induced C/EBP homology protein (CHOP) represses MyoD transcription to delay myoblast differentiation.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22242125","citation_count":44,"is_preprint":false},{"pmid":"26408402","id":"PMC_26408402","title":"Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26408402","citation_count":43,"is_preprint":false},{"pmid":"30337300","id":"PMC_30337300","title":"Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30337300","citation_count":43,"is_preprint":false},{"pmid":"22776069","id":"PMC_22776069","title":"Inhibition of CD200R1 expression by C/EBP β in reactive microglial cells.","date":"2012","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22776069","citation_count":42,"is_preprint":false},{"pmid":"19029947","id":"PMC_19029947","title":"SHARP1/DEC2 inhibits adipogenic differentiation by regulating the activity of C/EBP.","date":"2008","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/19029947","citation_count":41,"is_preprint":false},{"pmid":"25886310","id":"PMC_25886310","title":"DNA methyltransferase 1 functions through C/ebpa to maintain hematopoietic stem and progenitor cells in zebrafish.","date":"2015","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25886310","citation_count":40,"is_preprint":false},{"pmid":"31309149","id":"PMC_31309149","title":"Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31309149","citation_count":39,"is_preprint":false},{"pmid":"31100494","id":"PMC_31100494","title":"Estradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via ESR1-mediated activation of CEBPA.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31100494","citation_count":38,"is_preprint":false},{"pmid":"29886828","id":"PMC_29886828","title":"Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.","date":"2018","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29886828","citation_count":37,"is_preprint":false},{"pmid":"12970736","id":"PMC_12970736","title":"Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12970736","citation_count":37,"is_preprint":false},{"pmid":"23646198","id":"PMC_23646198","title":"Ablation of C/EBP homologous protein does not protect T17M RHO mice from retinal degeneration.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23646198","citation_count":35,"is_preprint":false},{"pmid":"26025484","id":"PMC_26025484","title":"CEBPA methylation and mutation in myelodysplastic syndrome.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26025484","citation_count":34,"is_preprint":false},{"pmid":"35178345","id":"PMC_35178345","title":"Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35178345","citation_count":34,"is_preprint":false},{"pmid":"30550771","id":"PMC_30550771","title":"Modulation of vitamin D signaling by the pioneer factor CEBPA.","date":"2018","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30550771","citation_count":34,"is_preprint":false},{"pmid":"18166146","id":"PMC_18166146","title":"C/EBP homologous protein is crucial for the acceleration of experimental pancreatitis.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18166146","citation_count":33,"is_preprint":false},{"pmid":"16220546","id":"PMC_16220546","title":"C/EBP homologous protein is necessary for normal osteoblastic function.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16220546","citation_count":33,"is_preprint":false},{"pmid":"30852139","id":"PMC_30852139","title":"Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30852139","citation_count":33,"is_preprint":false},{"pmid":"20829351","id":"PMC_20829351","title":"C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20829351","citation_count":31,"is_preprint":false},{"pmid":"25314137","id":"PMC_25314137","title":"Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25314137","citation_count":31,"is_preprint":false},{"pmid":"27927209","id":"PMC_27927209","title":"Coordinated inhibition of C/EBP by Tribbles in multiple tissues is essential for Caenorhabditis elegans development.","date":"2016","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/27927209","citation_count":30,"is_preprint":false},{"pmid":"19659458","id":"PMC_19659458","title":"Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia.","date":"2009","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19659458","citation_count":30,"is_preprint":false},{"pmid":"35080973","id":"PMC_35080973","title":"Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35080973","citation_count":29,"is_preprint":false},{"pmid":"31784538","id":"PMC_31784538","title":"Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31784538","citation_count":29,"is_preprint":false},{"pmid":"16909111","id":"PMC_16909111","title":"FMIP controls the adipocyte lineage commitment of C2C12 cells by downmodulation of C/EBP alpha.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16909111","citation_count":28,"is_preprint":false},{"pmid":"26278180","id":"PMC_26278180","title":"Structural Modeling of GR Interactions with the SWI/SNF Chromatin Remodeling Complex and C/EBP.","date":"2015","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26278180","citation_count":28,"is_preprint":false},{"pmid":"30679799","id":"PMC_30679799","title":"CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30679799","citation_count":27,"is_preprint":false},{"pmid":"21893041","id":"PMC_21893041","title":"Berberine exerts anti-adipogenic activity through up-regulation of C/EBP inhibitors, CHOP and DEC2.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21893041","citation_count":27,"is_preprint":false},{"pmid":"29884649","id":"PMC_29884649","title":"Impaired DNA demethylation of C/EBP sites causes premature aging.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/29884649","citation_count":26,"is_preprint":false},{"pmid":"34807506","id":"PMC_34807506","title":"METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.","date":"2021","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34807506","citation_count":26,"is_preprint":false},{"pmid":"32160715","id":"PMC_32160715","title":"lncRNA CEBPA-AS1 Overexpression Inhibits Proliferation and Migration and Stimulates Apoptosis of OS Cells via Notch Signaling.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32160715","citation_count":26,"is_preprint":false},{"pmid":"38755149","id":"PMC_38755149","title":"CEBPA restricts alveolar type 2 cell plasticity during development and injury-repair.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38755149","citation_count":25,"is_preprint":false},{"pmid":"30348891","id":"PMC_30348891","title":"Foxp3 expression in induced regulatory T cells is stabilized by C/EBP in inflammatory environments.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/30348891","citation_count":25,"is_preprint":false},{"pmid":"20671051","id":"PMC_20671051","title":"Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms.","date":"2010","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20671051","citation_count":25,"is_preprint":false},{"pmid":"31867767","id":"PMC_31867767","title":"Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.","date":"2019","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31867767","citation_count":24,"is_preprint":false},{"pmid":"27644413","id":"PMC_27644413","title":"Role of C/EBP-α in Adriamycin-induced podocyte injury.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27644413","citation_count":23,"is_preprint":false},{"pmid":"11012671","id":"PMC_11012671","title":"Regulation of Gadd45gamma expression by C/EBP.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11012671","citation_count":23,"is_preprint":false},{"pmid":"33831168","id":"PMC_33831168","title":"Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33831168","citation_count":23,"is_preprint":false},{"pmid":"37516962","id":"PMC_37516962","title":"CEBPA phase separation links transcriptional activity and 3D chromatin hubs.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37516962","citation_count":22,"is_preprint":false},{"pmid":"31075711","id":"PMC_31075711","title":"Shikonin induces apoptosis and suppresses growth in keratinocytes via CEBP-δ upregulation.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31075711","citation_count":22,"is_preprint":false},{"pmid":"31477806","id":"PMC_31477806","title":"Companion gene mutations and their clinical significance in AML with double mutant CEBPA.","date":"2019","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31477806","citation_count":22,"is_preprint":false},{"pmid":"23541085","id":"PMC_23541085","title":"Methylation status of CEBPA gene promoter in chronic myeloid leukemia.","date":"2013","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/23541085","citation_count":21,"is_preprint":false},{"pmid":"31829168","id":"PMC_31829168","title":"Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression.","date":"2019","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/31829168","citation_count":21,"is_preprint":false},{"pmid":"9406848","id":"PMC_9406848","title":"C/EBP activates the human corticotropin-releasing hormone gene promoter.","date":"1997","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9406848","citation_count":21,"is_preprint":false},{"pmid":"30073773","id":"PMC_30073773","title":"MiR-486 promotes proliferation and suppresses apoptosis in myeloid cells by targeting Cebpa in vitro.","date":"2018","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30073773","citation_count":21,"is_preprint":false},{"pmid":"18957690","id":"PMC_18957690","title":"The HIF-1 alpha-C/EBP alpha axis.","date":"2008","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/18957690","citation_count":20,"is_preprint":false},{"pmid":"34502076","id":"PMC_34502076","title":"MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502076","citation_count":19,"is_preprint":false},{"pmid":"30033148","id":"PMC_30033148","title":"The transcription factor C/EBP α controls the role of cystatin F during the differentiation of monocytes to macrophages.","date":"2018","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30033148","citation_count":19,"is_preprint":false},{"pmid":"22371011","id":"PMC_22371011","title":"Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22371011","citation_count":19,"is_preprint":false},{"pmid":"22715349","id":"PMC_22715349","title":"Asthma and COPD - The C/EBP Connection.","date":"2012","source":"The open respiratory medicine journal","url":"https://pubmed.ncbi.nlm.nih.gov/22715349","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46974,"output_tokens":6903,"usd":0.122233},"stage2":{"model":"claude-opus-4-6","input_tokens":10589,"output_tokens":3421,"usd":0.207705},"total_usd":0.329938,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"C/EBP (CEBPA) binds both the CCAAT homology and enhancer core homology sequences; a single gene product accounts for both binding activities, with a 14-kD DNA-binding domain identified by protease mapping, and a 60-amino-acid segment within this domain bears sequence similarity to myc and fos oncogenes.\",\n      \"method\": \"Bacterial expression of recombinant clone, in vitro DNA-binding assay, protease fragment analysis, sequence analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro binding with recombinant protein, domain mapping by proteolysis, foundational paper\",\n      \"pmids\": [\"2850264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"C/EBP alpha (CEBPA) protein is expressed in the late phase of adipocyte differentiation in 3T3-L1 cells, downstream of C/EBP beta and C/EBP delta, consistent with a regulatory cascade controlling terminal adipocyte differentiation; C/EBP beta and delta form heterodimers with C/EBP alpha and activate transcription from the serum albumin promoter.\",\n      \"method\": \"Western/Northern blotting during 3T3-L1 differentiation, transient transfection reporter assays, heterodimerization assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (expression timecourse, reporter assay, heterodimerization), highly cited foundational study\",\n      \"pmids\": [\"1840554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"C/EBP alpha (CEBPA) binds to and transactivates enhancer element II of hepatitis B virus in liver cells.\",\n      \"method\": \"EMSA (gel shift), transient cotransfection reporter assay\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro binding plus reporter assay, single lab\",\n      \"pmids\": [\"1853580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"C/EBP alpha (CEBPA) is required for hepatic glycogen storage, transcriptional induction of gluconeogenic enzymes (PEPCK and glucose-6-phosphatase), and lipid accumulation in hepatocytes and adipocytes; knockout mice die from neonatal hypoglycemia.\",\n      \"method\": \"Targeted gene deletion (knockout mouse), gene expression analysis, biochemical assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined phenotypic readouts, replicated through multiple metabolic endpoints\",\n      \"pmids\": [\"7652557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"C/EBP alpha binds to and transactivates the leptin gene promoter through a C/EBP binding motif; mutation of this motif reduces promoter activity approximately 10-fold and abolishes C/EBP alpha binding.\",\n      \"method\": \"Mutational analysis of promoter, EMSA, transient transfection reporter assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro binding and reporter assay with defined mutations, single lab\",\n      \"pmids\": [\"9492033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"C/EBP alpha (and C/EBP beta) induces both myeloid and eosinophil lineage commitment in multipotent hematopoietic progenitors; transactivation-independent C/EBP functions are required for eosinophil lineage commitment while transactivation-dependent functions are required for maturation.\",\n      \"method\": \"Forced expression of wild-type and transactivation-deficient C/EBP alleles in transformed multipotent progenitors (MEPs), conditional C/EBP allele activation, differentiation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — structure-function analysis with multiple mutant alleles and conditional activation, clear phenotypic readouts\",\n      \"pmids\": [\"9694805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Ras signaling enhances C/EBP alpha transcriptional activity to induce granulocytic differentiation by phosphorylation of serine 248 via a PKC-dependent pathway; S248A mutation abolishes both Ras-mediated transactivation enhancement and C/EBP alpha-induced granulocytic differentiation.\",\n      \"method\": \"Gal4-fusion transactivation assay, site-directed mutagenesis (S248A), in vivo phosphorylation assay, PKC inhibitor treatment, differentiation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — mutagenesis combined with in vivo phosphorylation assay and functional differentiation readout\",\n      \"pmids\": [\"11978795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Dominant-negative C/EBP (A-C/EBP) forms stable inactive heterodimers with C/EBP beta in vitro and blocks mitotic clonal expansion during adipogenesis by preventing nuclear import of C/EBP beta, thereby inhibiting expression of C/EBP alpha and PPARgamma downstream.\",\n      \"method\": \"Adenoviral A-C/EBP expression in 3T3-L1 cells, immunofluorescence staining, DNA replication assays, flow cytometry for cell cycle\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal epistasis established with multiple cellular readouts and mechanism (nuclear import blockade)\",\n      \"pmids\": [\"14688407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PI3K/Akt pathway activation in liver tumor cells causes PP2A-mediated dephosphorylation of C/EBP alpha at Ser193, blocking its growth inhibitory activity; mutation of Ser193 to Ala abolishes C/EBP alpha interaction with cdk2 and E2F-Rb complexes and prevents growth arrest.\",\n      \"method\": \"Site-directed mutagenesis (S193A), co-immunoprecipitation with cdk2 and E2F-Rb, growth arrest assay, pharmacological inhibition of PI3K/Akt and PP2A\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — mutagenesis with defined binding partners and functional readout, mechanistic pathway placement\",\n      \"pmids\": [\"15107404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FLT3-activating mutations in AML inhibit C/EBP alpha function through ERK1/2-mediated phosphorylation at serine 21; the S21A mutation restores granulocytic differentiation, while the phosphomimetic S21D mutation does not, demonstrating this is the relevant phosphorylation site.\",\n      \"method\": \"Site-directed mutagenesis (S21A, S21D), stable expression in MV4;11 cells, pharmacological inhibition of FLT3/MEK, granulocytic differentiation assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — mutagenesis with phosphomimetic controls and functional differentiation readout, clear mechanism\",\n      \"pmids\": [\"16446383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"C/EBP alpha genome-wide co-occupies approximately 3350 genomic regions together with PPARgamma in adipocytes; most adipogenesis-induced genes are bound by both factors, and both C/EBP alpha and beta are required along with PPARgamma for robust adipocyte-specific gene expression.\",\n      \"method\": \"ChIP-chip (ChIP coupled to genome-wide tiling arrays), ChIP in 3T3-L1 adipocytes\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP analysis with functional validation, highly cited\",\n      \"pmids\": [\"18981473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Calreticulin, induced by UPR/ER stress via the ATF6 pathway, binds to CEBPA mRNA and blocks its translation, suppressing C/EBP alpha protein expression and myeloid differentiation in AML.\",\n      \"method\": \"Conditional calreticulin expression in U937 cells, mRNA-protein interaction assay (calreticulin-CEBPA mRNA binding), reporter analysis of calreticulin promoter ERSE elements, patient sample analysis\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA-protein binding shown, functional consequence on CEBPA protein levels established, single lab\",\n      \"pmids\": [\"19659458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"C/EBP alpha directly regulates miR-34a expression during granulopoiesis; miR-34a targets E2F3 to block myeloid cell proliferation; AML samples with CEBPA mutations show reduced miR-34a and elevated E2F3 and E2F1.\",\n      \"method\": \"Reporter assay, ChIP, manipulation of miR-34a in AML blast cells, patient sample gene expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP shows direct binding, reporter assay confirms transcriptional regulation, functional rescue experiments\",\n      \"pmids\": [\"20889924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RUNX1 directly binds the CEBPA promoter and a conserved +37 kb enhancer region (with 4 Runx1 binding sites); RUNX1 loss reduces Cebpa mRNA in myeloid progenitors; exogenous C/EBP alpha rescues granulopoiesis in Runx1-deleted marrow, establishing RUNX1 as a direct upstream regulator of CEBPA.\",\n      \"method\": \"ChIP, enhancer mutagenesis in reporter assay, RUNX1-ER inducible system with cycloheximide, Runx1 knockout mice, exogenous C/EBP alpha rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, mutagenesis, inducible system, genetic rescue, multiple orthogonal methods\",\n      \"pmids\": [\"22451420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"C/EBP alpha controls adult HSC quiescence; C/EBP alpha-deficient adult HSCs show increased proliferation and number; N-Myc is identified as a downstream target of C/EBP alpha, and C/EBP alpha loss causes de-repression of N-Myc.\",\n      \"method\": \"Inducible Cebpa knockout mouse, transcriptional profiling, functional HSC assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible KO with defined molecular mechanism (N-Myc de-repression) and phenotypic readout\",\n      \"pmids\": [\"23502316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"p53 and KLF4 directly activate CEBPA gene transcription; in AML, p53 inactivation (correlated with elevated XPO1/CRM1, MDM2, CUL9/PARC) leads to reduced KLF4 and CEBPA protein levels; restoring p53 function induces CEBPA expression and myeloid differentiation.\",\n      \"method\": \"Reporter assays, protein level analysis in AML patient samples, pharmacological p53 restoration, differentiation assay\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay plus patient sample correlation plus pharmacological rescue, single lab\",\n      \"pmids\": [\"26408402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A single enhancer at +42 kb from CEBPA is essential for CEBPA expression exclusively in hematopoietic stem cells and myeloid-primed progenitors; germline deletion of this enhancer in mice causes severe granulocytic defects and loss of HSC maintenance without affecting CEBPA expression in other organs.\",\n      \"method\": \"CRISPR/Cas9 enhancer deletion in mice (in vivo), chromatin topology analysis, gene expression profiling in sorted progenitors\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vivo enhancer deletion with clean lineage-specific phenotype, multiple readouts\",\n      \"pmids\": [\"26966090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"R-2HG inhibits FTO demethylase activity, increasing global m6A RNA modification, which decreases the stability of CEBPA (and MYC) transcripts in sensitive leukemia cells, suppressing relevant signaling pathways.\",\n      \"method\": \"FTO activity assay, m6A RNA sequencing, mRNA stability assay, ectopic IDH1 mutation expression, FTO overexpression/knockdown\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — enzymatic assay, transcriptome-wide m6A analysis, functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"29249359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Small activating RNA (saRNA) targeting the CEBPA gene locus increases CEBPA transcription in a sequence-specific manner requiring Argonaute-2 (Ago2); the guide strand associates with Ago2 and localizes to the CEBPA genomic locus.\",\n      \"method\": \"Nuclear run-on assay, RNA ChIP (Ago2 association with CEBPA locus), saRNA gain-of-function in hepatocellular carcinoma cells\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — nuclear run-on confirms transcriptional mechanism, RNA-ChIP confirms locus-specific Ago2 association, single lab\",\n      \"pmids\": [\"28882451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Oncogenic C/EBP alpha p30 isoform (from N-terminal CEBPA mutations) physically interacts with the MLL1 histone-methyltransferase complex and co-localizes with MLL1 genome-wide; MLL1 complex loss causes differentiation arrest reversal in C/EBP alpha p30-expressing cells; GATA2 is identified as a direct critical target of the p30-MLL1 interaction.\",\n      \"method\": \"Co-immunoprecipitation (p30-MLL1 interaction), ChIP-seq (genome-wide co-localization), CRISPR/Cas9 MLL1 mutagenesis, pharmacological MLL1 complex inhibition, differentiation assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — reciprocal Co-IP, genome-wide ChIP-seq, CRISPR KO, pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"30679799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The leukemia-associated CEBPA-p30 isoform occupies aberrantly activated enhancers and directly drives Nt5e/CD73 expression; CD73 sustains leukemic growth via the CD73/A2AR axis; targeting this pathway enhances survival of AML-transplanted mice.\",\n      \"method\": \"Microscale in vivo ChIP-seq, cross-species gene expression analysis (human AML and Cebpa Lp30 mouse model), functional CD73/A2AR pathway inhibition in vivo\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq with cross-species validation and in vivo therapeutic targeting\",\n      \"pmids\": [\"31309149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Activating CSF3R mutations cooperate with loss-of-function CEBPA mutations to promote acute leukemia; mutant CEBPA prevents activation of a subset of myeloid lineage enhancers required for differentiation; CEBPA mutation must occur as the initial event in AML initiation.\",\n      \"method\": \"Mouse leukemia model with defined mutation order, chromatin/enhancer analysis, epistasis experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis with mutation order experiments and enhancer mechanism, single lab\",\n      \"pmids\": [\"31784538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Chronic IL-1β exposure selects for Cebpa-knockout hematopoietic progenitors because C/EBP alpha normally mediates IL-1β-induced differentiation and stem cell gene expression repression; Cebpa-KO HSPCs are resistant to these prodifferentiative effects and competitively expand; ectopic CEBPA reduces fitness of established human AML coinciding with increased differentiation.\",\n      \"method\": \"Competitive transplantation of Cebpa-KO vs wild-type HSPCs with chronic IL-1β treatment, gene expression profiling, ectopic CEBPA expression in human AML\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO in competitive in vivo setting with mechanistic gene expression data and human AML validation\",\n      \"pmids\": [\"33914855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CEBPA protein directly interacts with the long isoform DNMT3A (but not DNMT3A2) and blocks DNMT3A from accessing DNA substrate, thereby inhibiting its methyltransferase activity; tumor-associated CEBPA mutations (e.g., N321D) disrupt DNMT3A association and cause aberrant DNA hypermethylation at PRC2 target genes.\",\n      \"method\": \"Co-immunoprecipitation (CEBPA-DNMT3A interaction), in vitro methyltransferase activity assay with CEBPA blocking, bisulfite/methylation profiling of CEBPA mutant leukemia, mutagenesis of CEBPA interaction domain\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro enzymatic inhibition assay plus Co-IP, mutagenesis, and genome-wide methylation profiling\",\n      \"pmids\": [\"35080973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The intrinsically disordered region (IDR) of CEBPA undergoes phase separation in vitro dependent on aromatic residues; CEBPA forms nuclear foci and promotes long-range 3D chromatin hubs at CEBPA-bound regions during B cell-to-macrophage transdifferentiation; phase separation may underlie foci formation and 3D genome organization.\",\n      \"method\": \"In vitro phase separation assay with IDR mutagenesis, live-cell imaging of CEBPA foci, Hi-C/chromatin conformation analysis (ChIP-seq, ATAC-seq), transdifferentiation model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro reconstitution plus live imaging plus chromatin conformation data, IDR mutagenesis; phase separation-function link in vivo remains correlative\",\n      \"pmids\": [\"37516962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEBPA restricts alveolar type 2 (AT2) cell plasticity by promoting the AT2 transcriptional program and recruiting the lung lineage transcription factor NKX2-1; without CEBPA, neonatal AT2 cells reactivate the SOX9 progenitor program, and after Sendai virus injury mature AT2 cells also aberrantly express SOX9 and more readily form KRT8/CLDN4+ transitional cells.\",\n      \"method\": \"Conditional Cebpa knockout in AT2 cells, ChIP/co-immunoprecipitation for CEBPA-NKX2-1 interaction, ATAC-seq (epigenetic maturation), viral injury model, immunofluorescence\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined molecular mechanism (NKX2-1 recruitment), epigenetic data, injury model, multiple readouts\",\n      \"pmids\": [\"38755149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C/EBP alpha binds two regions of the bcl-2 P2 promoter and increases bcl-2 expression in t(14;18) lymphoma cells; siRNA-mediated knockdown of C/EBP alpha reduces Bcl-2 protein levels; in vivo binding confirmed by ChIP.\",\n      \"method\": \"Reporter assay, EMSA, ChIP, siRNA knockdown, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro binding, in vivo ChIP, and functional loss-of-function with protein readout\",\n      \"pmids\": [\"12970736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEBPA acts as a pioneer factor in THP-1 monocytes, co-occupying approximately one-third of genomic VDR binding sites; CEBPA binding strength is modulated by 1,25(OH)2D3; CEBPA silencing reveals it enhances basal expression and ligand-inducibility of ~70 vitamin D target genes and suppresses ~82 others, with PU.1 occupancy on CEBPA enhancers mechanistically explaining the dichotomy.\",\n      \"method\": \"ChIP-seq (CEBPA cistrome), RNA-seq after CEBPA silencing, ChIP for H3K4me3 and PU.1\",\n      \"journal\": \"Biochimica et biophysica acta. Gene regulatory mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq plus transcriptome after silencing, single lab\",\n      \"pmids\": [\"30550771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"STAT3 induces C/EBP alpha/beta expression, which suppresses MITF transcription by binding to the MITF enhancer region; ATAC-seq confirmed CEBPa/b binding to the MITF enhancer leads to silencing of the MITF locus in melanoma cells.\",\n      \"method\": \"STAT3 knockout mouse melanoma model, CEBP knockdown, ATAC-seq, gene expression profiling\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ATAC-seq confirms CEBP binding to MITF enhancer with KO/KD functional consequence, single lab\",\n      \"pmids\": [\"33323974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"C/EBP alpha (CEBPA) controls cystatin F expression by binding to the CST7 gene promoter during monocyte differentiation; upon PMA-induced differentiation to macrophages, C/EBP alpha protein level decreases and its binding to the CST7 promoter is reduced, leading to decreased cystatin F and increased intracellular cysteine cathepsin activity.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), co-immunoprecipitation, immunofluorescence confocal microscopy, proximity ligation assay\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct promoter binding, functional differentiation context established\",\n      \"pmids\": [\"30033148\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CEBPA encodes a bZIP transcription factor that directly binds CCAAT/enhancer DNA sequences and functions as a master regulator of myeloid and adipocyte differentiation by activating lineage-specific gene programs, maintaining HSC quiescence through repression of N-Myc, inhibiting cell-cycle progression via interactions with CDKs and E2F-Rb complexes, directly blocking DNMT3A methyltransferase activity through physical interaction, undergoing phase separation through its intrinsically disordered region to form 3D chromatin hubs, and serving as a hub for post-translational regulation—including ERK1/2-mediated phosphorylation at Ser21 (inhibitory) and Ras/PKC-mediated phosphorylation at Ser248 (activating)—whose disruption through recurrent mutations drives acute myeloid leukemia by causing aberrant enhancer activation, epigenetic dysregulation, and differentiation block.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CEBPA encodes a bZIP transcription factor that binds CCAAT/enhancer DNA sequences and serves as a master regulator of myeloid differentiation, adipogenesis, and hepatic metabolism. CEBPA activates lineage-specific gene programs in cooperation with PPARγ in adipocytes and PU.1 in myeloid cells, maintains hematopoietic stem cell quiescence through repression of N-Myc, and inhibits cell-cycle progression via phosphorylation-dependent interactions with CDK2 and E2F-Rb complexes [PMID:18981473, PMID:23502316, PMID:15107404]. Its activity is modulated by post-translational phosphorylation—ERK1/2-mediated phosphorylation at Ser21 inhibits granulocytic differentiation while PKC-mediated phosphorylation at Ser248 enhances it—and by direct physical inhibition of the DNMT3A methyltransferase, linking CEBPA to epigenetic regulation [PMID:16446383, PMID:11978795, PMID:35080973]. Loss-of-function and N-terminal truncating CEBPA mutations drive acute myeloid leukemia by causing aberrant enhancer activation through recruitment of the MLL1 complex, differentiation block, and DNA hypermethylation at PRC2 target genes [PMID:30679799, PMID:31784538, PMID:35080973].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"The initial question of what protein recognizes both CCAAT and enhancer core sequences was resolved by showing a single gene product (C/EBP) accounts for both activities, with a compact 14-kD DNA-binding domain bearing homology to myc/fos oncogenes, establishing CEBPA as a sequence-specific transcription factor.\",\n      \"evidence\": \"Recombinant protein expression, in vitro DNA-binding assay, and protease domain mapping\",\n      \"pmids\": [\"2850264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo target gene identification\", \"Dimerization partners not characterized\", \"No physiological function established\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"The physiological necessity of CEBPA was established by showing knockout mice die neonatally from hypoglycemia due to failed hepatic glycogen storage, gluconeogenic enzyme induction, and adipocyte lipid accumulation, defining CEBPA as essential for metabolic gene programs.\",\n      \"evidence\": \"Targeted gene deletion in mice with metabolic and gene expression phenotyping\",\n      \"pmids\": [\"7652557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hematopoietic role not yet addressed in KO\", \"Direct vs. indirect transcriptional targets not distinguished\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Beyond metabolism, CEBPA was shown to be sufficient to induce myeloid and eosinophil lineage commitment in multipotent progenitors, with transactivation-independent functions required for lineage specification and transactivation-dependent functions for maturation, revealing separable differentiation mechanisms.\",\n      \"evidence\": \"Forced expression of wild-type and transactivation-deficient alleles in multipotent progenitors with differentiation assays\",\n      \"pmids\": [\"9694805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo hematopoietic requirement not yet shown\", \"Downstream differentiation targets unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"How signaling pathways tune CEBPA activity was answered by identifying two opposing phosphorylation events: Ras/PKC-mediated Ser248 phosphorylation enhances granulocytic differentiation, while FLT3/ERK1/2-mediated Ser21 phosphorylation inhibits it, establishing post-translational control as a regulatory axis exploited in AML.\",\n      \"evidence\": \"Site-directed mutagenesis (S248A, S21A, S21D), in vivo phosphorylation assays, PKC/MEK inhibitors, granulocytic differentiation assays in MV4;11 cells\",\n      \"pmids\": [\"11978795\", \"16446383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full phosphoproteome of CEBPA not mapped\", \"Kinase-substrate interaction structures not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The mechanism by which CEBPA arrests cell growth was clarified: phosphorylation at Ser193 is required for physical interaction with CDK2 and E2F-Rb complexes, and PI3K/Akt-driven PP2A dephosphorylation at this site abolishes growth arrest, connecting metabolic signaling to cell-cycle control.\",\n      \"evidence\": \"S193A mutagenesis, co-immunoprecipitation with CDK2 and E2F-Rb, PI3K/Akt and PP2A pharmacological inhibition in liver tumor cells\",\n      \"pmids\": [\"15107404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CDK2/E2F interaction not resolved\", \"Relative contribution of each cell-cycle target unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genome-wide occupancy analysis revealed that CEBPA co-occupies ~3350 sites with PPARγ in adipocytes, establishing that the two factors cooperatively regulate the adipogenic transcriptional program rather than acting independently.\",\n      \"evidence\": \"ChIP-chip genome-wide tiling arrays in 3T3-L1 adipocytes\",\n      \"pmids\": [\"18981473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal hierarchy between CEBPA and PPARγ at co-bound sites not resolved\", \"Enhancer vs. promoter function not distinguished\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A key question about how HSCs maintain quiescence was addressed by showing that CEBPA-deficient adult HSCs hyperproliferate due to de-repression of N-Myc, establishing CEBPA as a direct regulator of HSC self-renewal independent of its differentiation function.\",\n      \"evidence\": \"Inducible Cebpa knockout mouse with transcriptional profiling and functional HSC assays\",\n      \"pmids\": [\"23502316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEBPA directly binds N-Myc regulatory regions not confirmed by ChIP\", \"Interaction with other quiescence regulators not explored\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The cis-regulatory architecture controlling tissue-specific CEBPA expression was defined by showing a single +42 kb enhancer is essential exclusively for hematopoietic CEBPA expression; its deletion causes granulocytic failure and HSC loss without affecting non-hematopoietic organs.\",\n      \"evidence\": \"CRISPR/Cas9 enhancer deletion in mice with sorted progenitor gene expression profiling\",\n      \"pmids\": [\"26966090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors at this enhancer beyond RUNX1 not fully defined\", \"Whether additional enhancers exist for fine-tuning within hematopoiesis\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"How N-terminal CEBPA mutations cause leukemia was mechanistically explained: the truncated p30 isoform recruits the MLL1 histone-methyltransferase complex to aberrant enhancers, directly activating GATA2 and the CD73/A2AR pathway to sustain leukemic growth and block differentiation.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation, ChIP-seq for p30 and MLL1, CRISPR MLL1 knockout, cross-species ChIP-seq, in vivo CD73 pathway inhibition\",\n      \"pmids\": [\"30679799\", \"31309149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How p30 gains MLL1 interaction absent in full-length CEBPA not structurally resolved\", \"Complete set of aberrant p30 target enhancers not cataloged\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A non-transcriptional function of CEBPA was uncovered: it directly binds the long DNMT3A isoform and physically blocks its access to DNA substrate, inhibiting methyltransferase activity; AML-associated C-terminal CEBPA mutations (e.g., N321D) disrupt this interaction, causing DNA hypermethylation at PRC2 targets.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro reconstituted methyltransferase inhibition assay, bisulfite methylation profiling of CEBPA-mutant leukemia\",\n      \"pmids\": [\"35080973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CEBPA-DNMT3A interface not determined\", \"Whether this mechanism operates in non-hematopoietic tissues unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CEBPA's intrinsically disordered region was shown to undergo phase separation in vitro and form nuclear foci that promote long-range 3D chromatin hubs during transdifferentiation, suggesting phase separation as a mechanism for CEBPA's pioneer-like genome reorganization activity.\",\n      \"evidence\": \"In vitro phase separation assay with IDR mutagenesis, live-cell imaging, Hi-C/chromatin conformation capture during B-to-macrophage transdifferentiation\",\n      \"pmids\": [\"37516962\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between phase separation and transcriptional output not established in vivo\", \"Whether phase separation is required for normal hematopoiesis untested\", \"IDR mutants not tested in differentiation functional assays\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CEBPA's role was extended beyond hematopoiesis: in alveolar type 2 cells, CEBPA recruits the lung lineage factor NKX2-1 to maintain the AT2 program and restrict plasticity; without CEBPA, cells reactivate the SOX9 progenitor program and aberrantly generate transitional cell states after injury.\",\n      \"evidence\": \"Conditional Cebpa knockout in AT2 cells, ChIP/co-IP for CEBPA-NKX2-1 interaction, ATAC-seq, Sendai virus injury model\",\n      \"pmids\": [\"38755149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEBPA-NKX2-1 interaction is direct or within a complex not resolved\", \"Relevance to lung fibrosis or adenocarcinoma progression not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CEBPA interactions with DNMT3A and MLL1, whether phase separation is functionally required for CEBPA's transcriptional and pioneer activities in vivo, the full spectrum of CEBPA's non-transcriptional functions, and how CEBPA integrates multiple post-translational modifications to coordinate differentiation versus quiescence decisions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of CEBPA-DNMT3A or CEBPA-MLL1 complex\", \"In vivo functional requirement for phase separation untested\", \"Combinatorial phosphorylation code not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 10, 27]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 5, 10, 13, 16, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [24, 25]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [10, 24, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 5, 10, 13, 16, 25, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 3, 5, 14, 25]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [8, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 19, 20, 21, 23]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [23, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PPARG\",\n      \"DNMT3A\",\n      \"MLL1\",\n      \"CDK2\",\n      \"NKX2-1\",\n      \"CEBPB\",\n      \"RUNX1\",\n      \"SPI1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}